Rapport Therapeutics, Inc.(RAPP) - 2025 Q3 - Quarterly Results

BUSINESS HIGHLIGHTS RAP-219 Lead Program Focal Onset Seizures (FOS) Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update BOSTON and SAN DIEGO, November 6, 2025 -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) ("Rapport" or the "Company"), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today reported financial results for the third quarter ending Sep ...